Ethics approval and consent to participate
Consent for publication
Availability of data and materials
Paolo A. Ascierto (PAA): Employment or leadership position: none; consultant/advisory role: Bristol-Meyers Squibb, Roche-Genentech, Merck Sharp & Dohme, Novartis, Merck Serono, Pierre-Fabre, AstraZeneca, Sun Pharma, Sanofi, Idera, Sandoz, Immunocore, 4SC, Italfarmaco, Nektar, Boehringer-Ingelheim, Eisai, Regeneron, Daiichi Sankyo, Pfizer, OncoSec, Nouscom, Lunaphore, Seagen, iTeos, Medicenna; stock ownership: none; research funding: Bristol-Meyers Squibb, Roche-Genentech, Pfizer, Sanofi; expert testimony: none; other remuneration: none.
Lisa H. Butterfield (LHB): LHB declares the following unrelated advisory activities (honoraria received): StemImmune/Calidi Scientific and Medical Advisory Board, April 6, 2017-present; Western Oncolytics, Scientific Advisory Board, 2018–2021; Torque Therapeutics, Scientific Advisory Board, 2018–2020; Khloris, Scientific Advisory Board, 2019–present; Pyxis, Scientific Advisory Board, 2019–present; Cytomix, Scientific Advisory Board, 2019–present; DCprime, Scientific Advisory Board meeting, Nov. 2020; RAPT, Scientific Advisory Board, 2020–present; Takeda, Scientific Advisor, 2020–present; EnaraBio scientific advisor, Feb. 2021.
Olivera J. Finn (OJF): no conflict to disclose.
Andrew Futreal (AF): Scientific Advisory Board for Scorpion Therapeutics.
Omid Hamid (OH): consulting/advisory boards: Aduro, Akeso, Amgen, Beigene, Bioatla, BMS, Roche Genentech, GSK, Immunocore, Idera, Incyte, Iovance, Janssen, Merck, Nextcure, Novartis, Pfizer, Sanofi/Regeneron, Seattle Genetics, Tempus, Zelluna; speaker bureau: BMS, Novartis, Pfizer, Sanofi/Regeneron; contracted research (for institution): Arcus, Aduro, Akeso, Amgen, Bioatla, BMS, CytomX, Exelixis, Roche Genentech, GSK, Immunocore, Idera, Incyte, Iovance, Merck, Moderna, Merck-Serono, NextCure, Novartis, Pfizer, Rubius, Sanofi/Regeneron, Seattle Genetics, Torque, Zelluna.
Theresa La Vallee (TLV): Parker Institute for Cancer Immunotherapy employment; Current employment at Coherus Biosciences; LISCure Biosciences Scientific Advisory Board, June 2020–present and stock ownership AstraZeneca; Consulting: TRex Bio, Grey Wolf Therapeutics, Exosis, BiOneCure. These are outside the scope of the submitted work. T.L. has no conflicts relating to the content of this work.
Michael A. Postow (MAP): consulting fees: BMS, Merck, Array BioPharma, Novartis, Incyte, NewLink Genetics, Aduro, Eisai, Pfizer. Honoraria: BMS and Merck. Institutional research support: RGenix, Infinity, BMS, Merck, Array BioPharma, Novartis, AstraZeneca.
Igor Puzanov (IP): consulting/honoraria: Nektar, Amgen, Roche, Oncorus; advisory board: Bristol-Myers Squibb, Nektar; institutional clinical trial support: Nektar, Idera, Oncosec, Amgen, Immunocore, Dynavax, Rubius, SQZ, ADC; DSMC: Nouscom; stock: Celldex.
Jeffrey Sosman (JS): research: Bristol Myers Squibb, Corvous, PACT; advisory board: Iovance, Nektar, Apixogen.
Bernard A. Fox (BAF): scientific advisory board (advising/consulting): Akoya/PerkinElmer, AstraZeneca/Definiens, Bristol-Myers Squibb, CanWell, Hookipa, Incyte, Macrogenics, NeoGenomics, PrimeVax (BOD, stock), Turnstone, UbiVac, Co-founder/CEO/stock, Ultivue. Research support: Akoya/PerkinElmer, Bristol-Myers Squibb, Definies/AstraZeneca, Incyte, Macrogenics, NanoString, OncoSec Shimadzu, Viralytics/Merck.
Patrick Hwu (PH): scientific advisory board: Immatics US, Inc., Dragonfly, GlaxoSmithKline, Sanofi Pasteur.